These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10333983)

  • 1. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.
    Curet O; Damoiseau-Ovens G; Sauvage C; Sontag N; Avenet P; Depoortere H; Caille D; Bergis O; Scatton B
    J Affect Disord; 1998 Dec; 51(3):287-303. PubMed ID: 10333983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
    Curet O; Damoiseau G; Aubin N; Sontag N; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):253-64. PubMed ID: 8613928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor.
    Rovei V; Caille D; Curet O; Ego D; Jarreau FX
    J Neural Transm Suppl; 1994; 41():339-47. PubMed ID: 7931248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission.
    Haddjeri N; De Montigny C; Curet O; Blier P
    Eur J Pharmacol; 1998 Feb; 343(2-3):179-92. PubMed ID: 9570466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats.
    Curet O; Damoiseau G; Labaune JP; Rovel V; Jarreau FX
    J Neural Transm Suppl; 1994; 41():349-55. PubMed ID: 7931249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone.
    Bottlaender M; Dolle F; Guenther I; Roumenov D; Fuseau C; Bramoulle Y; Curet O; Jegham J; Pinquier JL; George P; Valette H
    J Pharmacol Exp Ther; 2003 May; 305(2):467-73. PubMed ID: 12606609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects.
    Patat A; Berlin I; Durrieu G; Armand P; Fitoussi S; Molinier P; Caille P
    J Clin Pharmacol; 1995 Jun; 35(6):633-43. PubMed ID: 7665725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of dehydropirlindole and other compounds on rat brain monoamine oxidase type A.
    Gerardy J; Dresse A
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):75-9. PubMed ID: 11853123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute inhibition of cardiac monoamine oxidase A after tobacco smoke inhalation: validation study of [11C]befloxatone in rats followed by a positron emission tomography application in baboons.
    Valette H; Bottlaender M; Dollé F; Coulon C; Ottaviani M; Syrota A
    J Pharmacol Exp Ther; 2005 Jul; 314(1):431-6. PubMed ID: 15833896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of befloxatone: a brief review.
    Rosenzweig P; Patat A; Curet O; Durrieu G; Dubruc C; Zieleniuk I; Legangneux E
    J Affect Disord; 1998 Dec; 51(3):305-12. PubMed ID: 10333984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
    Dolle F; Valette H; Bramoulle Y; Guenther I; Fuseau C; Coulon C; Lartizien C; Jegham S; George P; Curet O; Pinquier JL; Bottlaender M
    Bioorg Med Chem Lett; 2003 May; 13(10):1771-5. PubMed ID: 12729662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
    Alemany R; Olmos G; García-Sevilla JA
    Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and subcellular distribution of [3H]rilmenidine binding sites in rat brain.
    Hosseini AR; Jackman GP; King PR; Louis WJ; Gundlach AL
    J Auton Nerv Syst; 1998 Oct; 72(2-3):129-36. PubMed ID: 9851561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reversible monoamine oxidase A inhibitor, befloxatone: structural approach of its mechanism of action.
    Wouters J; Moureau F; Evrard G; Koenig JJ; Jegham S; George P; Durant F
    Bioorg Med Chem; 1999 Aug; 7(8):1683-93. PubMed ID: 10482460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
    J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.
    Kagaya T; Kajiwara A; Nagato S; Akasaka K; Kubota A
    J Pharmacol Exp Ther; 1996 Jul; 278(1):243-51. PubMed ID: 8764357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.
    Flanagan S; Bartizal K; Minassian SL; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3060-6. PubMed ID: 23612197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered presynaptic function in monoaminergic neurons of monoamine oxidase-A knockout mice.
    Owesson CA; Hopwood SE; Callado LF; Seif I; McLaughlin DP; Stamford JA
    Eur J Neurosci; 2002 May; 15(9):1516-22. PubMed ID: 12028362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.